Patent · US Active

Prodrugs of riluzole and their method of use

US11440893B2 · kind B2 · utility

1Cited by

9References

5Claims

0Family size

Assignees

Inventors

Garry Robert Smith · Royersford, US
Allen B. Reitz · Lansdale, US
Mark McDonnell · Lansdale, US
Suzie Chen · Highland Park, US
Matthew D. Vera · West Haverstraw, US
Benjamin E. Blass · Eagleville, US
Jeffrey Claude Pelletier · Whitemarsh, US
Venkata Velvadapu · Ankeny, US
Jay E. Wrobel · Lawrenceville, US

Key dates

Filing date	Nov 23, 2020
Grant date	Sep 13, 2022
Priority date	—
Expiry date	Nov 23, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.